| Title: |
Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction |
| Authors: |
Mc Causland FR; Lefkowitz MP; Claggett B; Anavekar NS; Senni M; Gori M; Jhund PS; McGrath MM; Packer M; Shi V; Van Veldhuisen DJ; Zannad F; Comin-Colet J; Pfeffer MA; McMurray JJV; Solomon SD |
| Contributors: |
Mc Causland, F; Lefkowitz, M; Claggett, B; Anavekar, N; Senni, M; Gori, M; Jhund, P; Mcgrath, M; Packer, M; Shi, V; Van Veldhuisen, D; Zannad, F; Comin-Colet, J; Pfeffer, M; Mcmurray, J; Solomon, S |
| Publisher Information: |
Lippincott Williams and Wilkins; US |
| Publication Year: |
2020 |
| Collection: |
Università degli Studi di Milano-Bicocca: BOA (Bicocca Open Archive) |
| Subject Terms: |
Chronic; Heart failure; Renal insufficiency; Treatment outcome |
| Description: |
BACKGROUND: In patients with heart failure, chronic kidney disease is common and associated with a higher risk of renal events than in patients without chronic kidney disease. We assessed the renal effects of angiotensin/neprilysin inhibition in patients who have heart failure with preserved ejection fraction enrolled in the PARAGON-HF trial (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction). METHODS: In this randomized, double-blind, event-driven trial, we assigned 4822 patients who had heart failure with preserved ejection fraction to receive sacubitril/valsartan (n=2419) or valsartan (n=2403). Herein, we present the results of the prespecified renal composite outcome (time to first occurrence of either: ≥50% reduction in estimated glomerular filtration rate (eGFR), end-stage renal disease, or death from renal causes), the individual components of this composite, and the influence of therapy on eGFR slope. RESULTS: At randomization, eGFR was 63±19 mL·min–1·1.73 m–2. At study closure, the composite renal outcome occurred in 33 patients (1.4%) assigned to sacubitril/valsartan and 64 patients (2.7%) assigned to valsartan (hazard ratio, 0.50 [95% CI, 0.33–0.77]; P=0.001). The treatment effect on the composite renal end point did not differ according to the baseline eGFR ( |
| Document Type: |
article in journal/newspaper |
| File Description: |
STAMPA |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/32845715; info:eu-repo/semantics/altIdentifier/wos/WOS:000576528800005; volume:142; issue:13; firstpage:1236; lastpage:1245; numberofpages:10; journal:CIRCULATION; https://hdl.handle.net/10281/373122 |
| DOI: |
10.1161/CIRCULATIONAHA.120.047643 |
| Availability: |
https://hdl.handle.net/10281/373122; https://doi.org/10.1161/CIRCULATIONAHA.120.047643 |
| Rights: |
info:eu-repo/semantics/closedAccess ; license:Tutti i diritti riservati ; license uri:iris.PRI01 |
| Accession Number: |
edsbas.B321FA36 |
| Database: |
BASE |